HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Milano, A. D. Articles by Gallucci, V. Search for Related Content PubMed PubMed Citation Articles by Milano, A. D. Articles by Gallucci, V.

The Journal of Thoracic and Cardiovascular Surgery, Vol 98, 37-47, Copyright © 1989 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Aortic valve replacement with the Hancock standard, Bjork-Shiley, and Lillehei-Kaster prostheses. A comparison based on follow-up from 1 to 15 years

AD Milano, U Bortolotti, A Mazzucco, F Guerra, A Magni and V Gallucci
Department of Cardiovascular Surgery, University of Padova Medical School, Italy.

Three series of patients undergoing isolated aortic valve replacement with the standard glutaraldehyde-preserved Hancock porcine bioprosthesis, the standard Bjork-Shiley spherical disc prosthesis, and the Lillehei-Kaster tilting disc prosthesis were compared during a 15- year follow-up. From March 1970 to December 1985, aortic valve replacement was performed in 506 patients, 379 men and 109 women, whose ages ranged from 17 to 71 years (mean, 47 +/- 12 years); 196 had a Hancock bioprosthesis, 147 a Bjork-Shiley prosthesis, and 163 a Lillehei-Kaster prosthesis. There were no significant differences among the three groups in terms of mean age, preoperative New York Heart Association class, valve lesion, associated intracardiac procedures, and operative mortality (11.7% for the Hancock bioprosthesis group, 8.8% for the Bjork-Shiley prosthesis group, and 9.2% for the Lillehei- Kaster prosthesis group). Cumulative duration of follow-up is 1140 patient-years (mean, 6.6 +/- 1.5 years, 100% complete) for Hancock bioprosthesis patients, 878 patient-years (mean, 5.9 +/- 0.4 years, 98% complete) for Bjork-Shiley prosthesis patients, and 1184 patient-years (mean, 7.3 +/- 0.3 years, 97% complete) for Lillehei-Kaster prosthesis patients. Actuarial survival rates at 15 years are 30% +/- 15% for Hancock bioprosthesis, 49% +/- 6% for Bjork-Shiley prosthesis, and 44% +/- 7% for Lillehei-Kaster prosthesis patients. There were eight embolic episodes in Hancock valve recipients (0.7% +/- 0.1%/pt-yr), nine in Bjork-Shiley prosthesis recipients (1.0% +/- 0.3%/pt-yr), and nine (0.7% +/- 0.1%/pt-yr) in Lillehei-Kaster prosthesis recipients (p = no significant difference). Actuarial freedom from emboli at 15 years is 89% +/- 4% for Hancock, 92% +/- 3% for Bjork-Shiley, and 93% +/- 2% for Lillehei-Kaster prosthesis recipients (p = no significant difference). A significant difference was found in the incidence of the following complications. (1) Anticoagulant-related hemorrhage: 0.1% +/- 0.1%/pt-yr for Hancock bioprosthesis, 1.3% +/- 0.3%/pt-yr for Bjork- Shiley prosthesis, and 1.9% +/- 0.4%/pt-yr for Lillehei-Kaster prosthesis patients (p less than 0.001), with an actuarial freedom at 15 years of 97.6% +/- 1% for Hancock, 85% +/- 5% for Bjork-Shiley, and 68.8% +/- 10% for Lillehei-Kaster recipients (p less than 0.001). (2) Structural deterioration: 3.7% +/- 0.6%/pt-yr for Hancock and none for Bjork-Shiley and Lillehei-Kaster patients (p less than 0.001), with an actuarial freedom of 100% for Bjork-Shiley prosthesis and Lillehei- Kaster prosthesis patients and 38.4% +/- 12% for Hancock bioprosthesis patients at 15 years.

This article has been cited by other articles:

				S. John, E. Ravikumar, C. N. John, and V. V. Bashi 25-year experience with 456 combined mitral and aortic valve replacement for rheumatic heart disease Ann. Thorac. Surg., April 1, 2000; 69(4): 1167 - 1172. [Abstract] [Full Text] [PDF]

				D. S. Peterseim, Y.-Y. Cen, S. Cheruvu, K. Landolfo, T. M. Bashore, J. E. Lowe, W. G. Wolfe, and D. D. Glower LONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS J. Thorac. Cardiovasc. Surg., May 1, 1999; 117(5): 890 - 897. [Abstract] [Full Text] [PDF]

				T. A. Orszulak, H. V. Schaff, C. J. Mullany, B. J. Anderson, D. M. Ilstrup, F. J. Puga, and G. K. Danielson Risk of Thromboembolism With the Aortic Carpentier-Edwards Bioprosthesis Ann. Thorac. Surg., February 1, 1995; 59(2): 462 - 468. [Abstract] [Full Text]